Serum-Based MicroRNA Signatures in Early Diagnosis and Prognosis Prediction of Colon Cancer

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Authors

VYCHYTILOVÁ Petra RADOVÁ Lenka ŠACHLOVÁ Milana KOSAŘOVÁ Zdeňka SLABÁ Kateřina FABIAN Pavel GROLICH Tomáš PROCHÁZKA Vladimír KALA Zdeněk SVOBODA Marek KISS Igor VYZULA Rostislav SLABÝ Ondřej

Year of publication 2016
Type Article in Periodical
Magazine / Source Carcinogenesis
MU Faculty or unit

Central European Institute of Technology

Citation
Web https://academic.oup.com/carcin/article-abstract/37/10/941/2196570/Serum-based-microRNA-signatures-in-early-diagnosis?redirectedFrom=fulltext
Doi http://dx.doi.org/10.1093/carcin/bgw078
Field Oncology and hematology
Keywords microRNA; colorectal cancer; blood serum; diagnostic biomarker; prognostic biomarker
Attached files
Description Early detection of colorectal cancer is the main prerequisite for successful treatment and reduction of mortality. Circulating microRNAs were previously identified as promising diagnostic, prognostic and predictive biomarkers. The purpose of the present study was to identify serum microRNAs enabling early diagnosis and prognosis prediction of colon cancer. In total, serum samples from 427 colon cancer patients and 276 healthy donors were included in 3-phase biomarker study. Large-scale microRNA expression profiling was performed using Illumina small RNA sequencing. Diagnostic and prognostic potential of identified microRNAs was validated on independent training and validation sets of samples using RT-qPCR. Fifty-four microRNAs were found to be significantly deregulated in serum of colon cancer patients compared to healthy donors (P < 0.01). A diagnostic 4-microRNA signature consisting of miR-23a-3p, miR-27a-3p, miR-142-5p and miR-376c-3p was established (AUC = 0.917), distinguishing colon cancer patients from healthy donors with sensitivity of 89% and specificity of 81% (AUC = 0.922). This panel of microRNAs exhibited high diagnostic performance also when analyzed separately in colon cancer patients in early stages of the disease (T1-4N0M0; AUC = 0.877). Further, a prognostic panel based on the expression of miR-23a-3p and miR-376c-3p independent of TNM stage was established (HR 2.30; 95% CI 1.44-3.66; P < 0.0004). In summary, highly sensitive signatures of circulating microRNAs enabling non-invasive early detection and prognosis prediction of colon cancer were identified.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.